CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Study Summary

There are limited options for treatment of relapse/refractory acute myeloid leukemia (AML). CD123 CAR-T cells may have an attractive and permanent effect on anti-tumor. This study purpose to estimate the safety and efficiency of CD123 CAR-T cells to patients with relapse/refractory AML.

Interventions

Study Locations

Facility	City	State	Country
920th Hospital of Joint Logistics Support Force	Kunming	Yunnan	China

Official Trial Information

View on ClinicalTrials.gov